During the SARS-CoV-2 virus pandemic, which began in 2019, it has been observed that the vast majority of people have a mild clinical picture or asymptomatic COVID-19. However, approximately 10% of individuals infected with the virus will have a severe, potentially fatal clinical course associated with hyperinflammation, vascular endothelial damage, thrombotic complications and lung injury. To predict and make prognoses about course of COVID-19, it is necessary to understand the immunologic mechanisms induced after the infection. Knowledge of the infection immunopathology is essential for development of effective immunomodulatory therapy. The paper describes selected plant-derived immunomodulators that may exhibit preventive and soothing effects on COVID-19 disease symptoms.